Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
4.040
+0.040 (1.00%)
At close: Oct 21, 2025, 4:00 PM EDT
4.010
-0.030 (-0.74%)
After-hours: Oct 21, 2025, 4:41 PM EDT
Altimmune Employees
Altimmune had 59 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
59
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$339
Profits / Employee
-$1,487,220
Market Cap
356.56M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 59 | 0 | - |
Dec 31, 2023 | 59 | 7 | 13.46% |
Dec 31, 2022 | 52 | 5 | 10.64% |
Dec 31, 2021 | 47 | 4 | 9.30% |
Dec 31, 2020 | 43 | 18 | 72.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALT News
- 1 day ago - Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 15 days ago - ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline - GlobeNewsWire
- 15 days ago - ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewsWire
- 18 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - PRNewsWire
- 21 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewsWire
- 22 days ago - Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide - GlobeNewsWire
- 4 weeks ago - Altimmune to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewsWire